We also demonstrated that targeting TNK2 with specific siRNA/shRNA can substantially attenuate oncogenic phenotypes of TNBC cells in vitro and, more importantly, dramatically reduce tumor formation in preclinical xenograft mouse models, suggesting that these aggressive characteristics are driven by TNK2. The gene discussed is TNK2; the disease is neoplasm.